Contact – +1-276-477-5910
 Email – [email protected]

Home >>

Healthcare and Social Assistance

>>

Business Opportunities and Investment Strategies for Global Recombinant Cell Culture Supplements Market


Business Opportunities and Investment Strategies for Global Recombinant Cell Culture Supplements Market 2023-2033

Report code: SDMRGM1703188 | Industry: Healthcare and Social Assistance | Published On: 2024-06-07


Opportunity and Strategy Analysis
This report focuses on identifying opportunities and strategies for investing in the global recombinant cell culture supplements market within the forecast period. It provides a complete analysis of the global market both quantitatively and qualitatively. The quantitative analysis includes market size and revenue data of the total demand, sub-markets, and regional/national levels throughout 2023-2033. Qualitative analysis depicts a full picture of market dynamics and trends including drivers, restraints and challenges, emerging products/market trends, and Porter’s Fiver Forces analysis.

Based on the market data and analysis, the report highlights Increasingly Attractive Segments (IAS) and business opportunities in each segmentation. Moreover, a systematic evaluation of Internal Risks (factors arising within the industry development) and External Risks (factors arising from the surrounding environments) is provided for the recombinant cell culture supplements industry and market. All the identified risk factors are measured quantitatively according to GMD’s novel numeric system, i.e. each risk is evaluated with GMD Risk Index Number (GMD RIN) and GMD Risk Intensity Level (GMD RIL). This in-depth risk assessment offers a comprehensive understanding of the current risk factors and their developing trends. Furthermore, this report concludes risk management strategies and Critical Success Factors (CSFs) to help companies make intelligence-based business decisions in the global recombinant cell culture supplements industry.

Market Coverage & Overview
The report is based on studies for 2021-2023 and provides a forecast from 2024 till 2033 with 2023 as the base year. Considering impact of COVID-19 and regional conflicts such as Russia-Ukraine war, the trend and outlook of global market is forecast in optimistic, balanced, and conservative scenarios. In the balanced view, the global recombinant cell culture supplements market is expected to reach $1.42 billion by 2033, growing by 10.5% annually over the coming years.

Segmentation Analysis
Highlighted with 91 tables and 108 figures, this 224-page report represents a 360-degree view on the global market with extensively detailed segmentations by Product, Source, Expression System, Application, End User, and Region/Country as shown below. Annual revenue 2023-2033 for each segment is included in the report.

By Product
• Recombinant Albumin (rAlbumin)
• Recombinant Insulin (rInsulin)
• Recombinant Epidermal Growth Factor (rEGF)
• Recombinant Interleukin Growth Factor (rILGF)
• Recombinant Transferrin (rTransferrin)
• Recombinant Trypsin (rTrypsin)
• Recombinant Insulin-like Growth Factor (rIGF)
• Recombinant Stem Cell Factor (rSCF)
• Recombinant Aprotinin (rAprotinin)
• Recombinant Lysozyme (rLysozyme)
• Other Products

By Source
• Animals
• Human
• Microorganisms

By Expression System
• Mammalian
• E. Coli
• Yeast
• Other Expression Systems

By Application
• Stem Cell and Regenerative Medicine
o Stem Cell Therapies
o Cell Therapies
o Gene Therapies and Others
• Bio-Production
o Monoclonal Antibodies
o Recombinant Proteins
o Hormones
o Vaccines
o Other Biological Products
• Academic Research

By End User
• Biopharmaceutical Companies
• Contract Research Centers (CROs)
• Academic & Research Institutes

By Region
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, and Rest of MEA)
The breakdown of all regional markets by country and the breakdown of each national market by Product, Expression System, and Application over the forecast years are also included.

Key Companies
The report also covers the current competitive scenario and profiles key vendors including market leaders and important emerging players. A selection of companies profiled in this report includes:
• Abcam plc.
• BBI Solutions OEM Limited
• Becton, Dickinson and Company
• Cell Sciences, Inc.
• Corning Incorporated
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Irvine Scientific, Inc.
• Gemini Bioproducts, LLC
• HiMedia Laboratories, LLC
• InVitria
• Kingfisher Biotech, Inc.
• Lonza Group AG
• Merck KGaA
• Novus Biologicals, LLC
• R&D Systems, Inc.
• Sartorius AG
• Sino Biological Inc.
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc.

1  Introduction 12
1.1  Industry  Definition  and  Research  Scope 12
1.1.1  Industry  Definition 12
1.1.2  Research  Scope 13
1.2  Research  Methodology 16
1.2.1  Overview  of  Market  Research  Methodology 16
1.2.2  Market  Assumption 17
1.2.3  Secondary  Data 17
1.2.4  Primary  Data 17
1.2.5  Data  Filtration  and  Model  Design 18
1.2.6  Market  Size/Share  Estimation 19
1.2.7  Research  Limitations 20
1.3  Executive  Summary 21
2  Market  Overview  and  Dynamics 24
2.1  Market  Size  and  Forecast 24
2.1.1  Impact  of  COVID-19  on  World  Economy 25
2.1.2  Impact  of  COVID-19  on  the  Market 29
2.1.3  Impact  of  Russia-Ukraine  Conflict 31
2.1.4  Impact  of  Israel-Palestine  War 33
2.2  Major  Growth  Drivers 34
2.3  Market  Restraints  and  Challenges 39
2.4  Emerging  Opportunities  and  Market  Trends 42
2.5  Porter’s  Fiver  Forces  Analysis 45
3  Segmentation  of  Global  Market  by  Product 49
3.1  Market  Overview  by  Product 49
3.2  Recombinant  Albumin  (rAlbumin) 52
3.3  Recombinant  Insulin  (rInsulin) 53
3.4  Recombinant  Epidermal  Growth  Factor  (rEGF) 54
3.5  Recombinant  Interleukin  Growth  Factor  (rILGF) 55
3.6  Recombinant  Transferrin  (rTransferrin) 56
3.7  Recombinant  Trypsin  (rTrypsin) 57
3.8  Recombinant  Insulin-like  Growth  Factor  (rIGF) 58
3.9  Recombinant  Stem  Cell  Factor  (rSCF) 59
3.10  Recombinant  Aprotinin  (rAprotinin) 60
3.11  Recombinant  Lysozyme  (rLysozyme) 61
3.12  Other  Products 62
4  Segmentation  of  Global  Market  by  Source 63
4.1  Market  Overview  by  Source 63
4.2  Animals 66
4.3  Human 67
4.4  Microorganisms 68
5  Segmentation  of  Global  Market  by  Expression  System 69
5.1  Market  Overview  by  Expression  System 69
5.2  Mammalian 72
5.3  E.  Coli 73
5.4  Yeast 74
5.5  Other  Expression  Systems 75
6  Segmentation  of  Global  Market  by  Application 76
6.1  Market  Overview  by  Application 76
6.2  Stem  Cell  and  Regenerative  Medicine 79
6.2.1  Stem  Cell  Therapies 80
6.2.2  Cell  Therapies 81
6.2.3  Gene  Therapies  and  Others 82
6.3  Bio-Production 83
6.3.1  Monoclonal  Antibodies 85
6.3.2  Recombinant  Proteins 86
6.3.3  Hormones 87
6.3.4  Vaccines 88
6.3.5  Other  Biological  Products 89
6.4  Academic  Research 90
7  Segmentation  of  Global  Market  by  End  User 91
7.1  Market  Overview  by  End  User 91
7.2  Biopharmaceutical  Companies 94
7.3  Contract  Research  Centers  (CROs) 95
7.4  Academic  &  Research  Institutes 96
8  Segmentation  of  Global  Market  by  Region 97
8.1  Geographic  Market  Overview  2023-2033 97
8.2  North  America  Market  2023-2033  by  Country 102
8.2.1  Overview  of  North  America  Market 102
8.2.2  U.S. 106
8.2.3  Canada 110
8.2.4  Mexico 113
8.3  European  Market  2023-2033  by  Country 116
8.3.1  Overview  of  European  Market 116
8.3.2  Germany 120
8.3.3  U.K. 123
8.3.4  France 126
8.3.5  Spain 129
8.3.6  Italy 132
8.3.7  Russia 135
8.3.8  Rest  of  European  Market 138
8.4  Asia-Pacific  Market  2023-2033  by  Country 140
8.4.1  Overview  of  Asia-Pacific  Market 140
8.4.2  Japan 144
8.4.3  China 148
8.4.4  Australia 151
8.4.5  India 154
8.4.6  South  Korea 157
8.4.7  Rest  of  APAC  Region 160
8.5  South  America  Market  2023-2033  by  Country 162
8.5.1  Argentina 166
8.5.2  Brazil 169
8.5.3  Chile 172
8.5.4  Rest  of  South  America  Market 175
8.6  MEA  Market  2023-2033  by  Country 176
8.6.1  UAE 180
8.6.2  Saudi  Arabia 183
8.6.3  South  Africa 186
8.6.4  Other  National  Markets 189
9  Competitive  Landscape 190
9.1  Overview  of  Key  Vendors 190
9.2  New  Product  Launch,  Partnership,  Investment,  and  M&A 193
9.3  Company  Profiles 194
Abcam  plc. 194
BBI  Solutions  OEM  Limited 196
Becton,  Dickinson  and  Company 197
Cell  Sciences,  Inc. 198
Corning  Incorporated 199
F.  Hoffmann-La  Roche  Ltd. 200
FUJIFILM  Irvine  Scientific,  Inc. 201
Gemini  Bioproducts,  LLC 202
HiMedia  Laboratories,  LLC 203
InVitria 204
Kingfisher  Biotech,  Inc. 205
Lonza  Group  AG 206
Merck  KGaA 207
Novus  Biologicals,  LLC 208
R&D  Systems,  Inc. 209
Sartorius  AG 210
Sino  Biological  Inc. 211
STEMCELL  Technologies  Inc. 212
Thermo  Fisher  Scientific  Inc. 213
10  Investing  in  Recombinant  Cell  Culture  Supplements  Industry:  Risk  Assessment  and  Management 214
10.1  Risk  Evaluation  of  Global  Market 214
10.2  Critical  Success  Factors  (CSFs) 221
RELATED  REPORTS 224
To know more, kindly contact [email protected]
 Feel free to contact us

 
Choose License Type
Select User Type


Report code




x

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT